ERBB2 and breast carcinoma: Therefore, we generated anti-HER2 resistant cells by continuously exposing trastuzumab-sensitive HER2-positive breast cancer cell lines SKBR3, BT474, and AU565 to trastuzumab for 3 months in vitro (Supplementary Fig. 1a).